Delivering Advanced Therapeutics
CP018 Risperidone Depot
CP018 is a long-acting injection of risperidone that uses Critical Pharmaceuticals’ proprietary CriticalMix™ drug delivery technology. It is being developed as a once every two week injection.
Risperidone is the most widely prescribed medication in its class for the treatment of schizophrenia and other psychiatric disorders and is the only drug approved by the FDA for the treatment of schizophrenia in adolescents. Risperidone is effective against both the positive and negative symptoms of schizophrenia and produces fewer side effects than conventional antipsychotic drugs. Schizophrenia effects more than 24 million people worldwide and global sales for risperidone is currently estimated to be $4.2 billion annually.
Several oral atypical antipsychotics are available for the management of schizophrenia but their benefits are limited by non-compliance. Long-acting injectable risperidone makes an important contribution to the management of schizophrenia by ensuring greater patient compliance and CP018 is an attractive alternative to current therapies.